Setting a specific, attainable New Year's resolution is key to following through, says columnist Leigh Anne Nelson, who ...

Patient enrollment is completed ahead of schedule for Contineum's Phase 2 clinical trial of PIPE-307, an oral remyelination ...

A Phase 1 trial that is testing Modex's vaccine against the Epstein-Barr virus, a strong risk factor for MS, has dosed its ...

Immunic Therapeutics says it's "on track" in its MS clinical trials of vidofludimus calcium, with CALLIPER top-line data ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

Columnist Ahna Crum is taking on a new year with a different approach: meeting the day-to-day new beginnings in life with ...

Scientists say IRX4204 given to mice with evident symptoms showed potential "as a remyelinating and neurorestorative ...

Long-term Tecfidera use was found to significantly reduce relapse rates and slow disability progression for MS patients in a ...

Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...

Certain health issues seen in youth with MS in the five years before diagnosis confirm a prodromal period may exist in ...

Columnist Ben Hofmeister explains a handy acronym that's helped him and can help you motivate yourself with MS.

MS patients show large differences between vascular age and chronological age, even if they don't have cardiovascular disease ...